Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

426
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
426
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

108
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
108
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

308
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
308
Peptic Ulcer Disease V: Surgical Management and Nursing Care01:25

Peptic Ulcer Disease V: Surgical Management and Nursing Care

324
Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease
324
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

151
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
151
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

443
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
443

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A cluster randomized trial of a Multicomponent Clinical Care Pathway (MCCP) to improve MASLD diagnosis and management in primary care: study protocol.

BMC health services research·2025
Same author

HES V2.0 surpasses GALAD for HCC detection: a review of multi-dimensional biomarker scores and studies.

Hepatic oncology·2025
Same author

A Simple, Interpretable Machine Learning Model Based on Clinical Factors Accurately Predicts Incident Dysplasia or Malignancy in Barrett's Esophagus.

Digestive diseases and sciences·2025
Same author

Shared genetic architecture of non-viral cirrhosis with several pleiotropic traits: A nested case-control study in the UK Biobank.

Liver international communications·2025
Same author

Impact of an Electronic Medical Record Quality Improvement Intervention on Helicobacter pylori Treatment and Eradication Rates in a U.S. Hospital System.

Helicobacter·2025
Same author

High Risk of Persistence and Risk of Dysplasia After Diagnosis of Ultrashort Barrett's Esophagus.

The American journal of gastroenterology·2025

Related Experiment Video

Updated: Jul 14, 2025

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

389

Evolving Concepts in Helicobacter pylori Management.

Steven F Moss1, Shailja C Shah2, Mimi C Tan3

  • 1Brown University, Providence, Rhode Island; Providence VA Medical Center, Providence, Rhode Island.

Gastroenterology
|October 8, 2023
PubMed
Summary

Helicobacter pylori (H pylori) infection is a major risk for gastric cancer, especially in minority groups. A systematic screening and personalized treatment approach is crucial for effective prevention.

Keywords:
Antibiotic ResistanceGastric CancerGastric Cancer ScreeningGastric Intestinal MetaplasiaH pylori TreatmentHelicobacter pyloriSusceptibility TestingUnder-represented Minorities

More Related Videos

Author Spotlight: Detection and Treatment of Helicobacter pylori Infection
06:40

Author Spotlight: Detection and Treatment of Helicobacter pylori Infection

Published on: July 28, 2023

3.3K
Rapid Detection of Helicobacter pylori Virulence and Typing Using Quantum Dot Labeling Technology
05:13

Rapid Detection of Helicobacter pylori Virulence and Typing Using Quantum Dot Labeling Technology

Published on: June 13, 2025

85

Related Experiment Videos

Last Updated: Jul 14, 2025

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
05:23

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

389
Author Spotlight: Detection and Treatment of Helicobacter pylori Infection
06:40

Author Spotlight: Detection and Treatment of Helicobacter pylori Infection

Published on: July 28, 2023

3.3K
Rapid Detection of Helicobacter pylori Virulence and Typing Using Quantum Dot Labeling Technology
05:13

Rapid Detection of Helicobacter pylori Virulence and Typing Using Quantum Dot Labeling Technology

Published on: June 13, 2025

85

Area of Science:

  • Infectious Diseases
  • Gastroenterology
  • Oncology

Background:

  • Helicobacter pylori (H pylori) is the leading cause of gastric cancer globally.
  • H pylori infection and gastric cancer disproportionately affect minority and immigrant populations in the US.
  • Current opportunistic H pylori screening misses many asymptomatic infections, delaying diagnosis of preneoplastic lesions.

Purpose of the Study:

  • To advocate for a systematic approach to H pylori screening and management.
  • To address declining eradication rates and increasing antimicrobial resistance.
  • To emphasize personalized treatment strategies for H pylori infection.

Main Methods:

  • Review of current H pylori case-finding and treatment strategies.
  • Discussion of the limitations of empirical H pylori therapies.
  • Highlighting the potential of molecular-based susceptibility profiling for personalized treatment.

Main Results:

  • Opportunistic H pylori testing is insufficient for comprehensive gastric cancer prevention.
  • Standard H pylori eradication therapies show decreasing efficacy due to antimicrobial resistance.
  • Molecular susceptibility testing enables tailored H pylori treatment regimens.

Conclusions:

  • A shift towards systematic H pylori screening and personalized eradication is needed.
  • Population-level screening and treatment programs can reduce gastric cancer burden.
  • Targeting high-risk minority and marginalized populations is essential for equitable gastric cancer prevention.